Sky-High Cardiovascular Device Valuations
Despite-or perhaps because of-all of the recent consolidation in cardiovascular devices, investor interest in small technology companies appears, if anything, to be getting hotter.
You may also be interested in...
Only about one-quarter of the 40 gene therapies projected to launch by the end of 2025 would have potential US patient populations of more than 50,000. But a handful of treatments could target millions of individuals.
With the era of medical automation upon us, surgeons are increasingly turning to robots and artificial intelligence for better results in the operating suite. See what Frank Pasquale, professor at Brooklyn Law School and author of the book New Laws of Robotics: Defending Human Expertise in the Age of AI, said about it here.
Cancer drug developers should come to the agency early with a package of clinical trials to support accelerated approval and confirm clinical benefit rather than with plans to sequentially conduct such studies, Oncology Center of Excellence’s Richard Pazdur says; he also suggests closer scrutiny ahead of whether postmarketing trials are being conducted with ‘due diligence.’